Trial · NCT02441660
Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain
NCT02441660, Not applicable, Completed, The University of Texas Health Science Center at San Antonio; results first posted 2022-10-06
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain. Trials, record NCT02441660. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02441660
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Capsaicin 8% Patch for Spinal Cord Injury Neuropathic Pain
- NCT number
- NCT02441660
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 11 participants, actual
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Conditions
- Spinal Cord Injuries, Neuropathic Pain
- Interventions
- Capsaicin 8% Patch, Low Dose Capsaicin 0.025% Well Patch
- First posted
- 2015-05-12
- Last updated
- 2023-01-26
- Results first posted
- 2022-10-06
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Pain Relief With Visual Analog (VAS) Pain Scale | Change in pain at 2,4,6,8, 10 and 12 weeks | The Visual Analog Scale (VAS) was used as the primary outcome measure to quantify pain on a scale of 0-10, with 0 being no pain and 10 being the worst pain. VAS was measured at weeks 2,4,6,8,10 and12 during each 12- week block. |
| Primary | Change in Quality of Life as Measured by the World Health Organization Quality of Life (WHOQOL-BREF) | Every 4 weeks for 12 weeks | The World Health Organization Quality of Life (WHOQOL-BREF) questionnaire is a scale used to assess an individual's perception of their quality of life. Its domains include physical health, psychological health, social relationships, and patient environment. It is scored from 0-100, where lower scores indicate poorer perception of quality of life and higher scores indicate better perception. This scale was used to investigate if there was any pattern of change in QOL due to improved pain control. WHO-QOL-BREF was also measured every 4 weeks of each period. |
| Primary | Change in Spinal Cord Independence Measure (SCIM) | Every 4 weeks for12 weeks | The Spinal Cord Independence Measure (SCIM) is a reliable scale that measures proficiency of activities of daily living (ADL's) of patients with spinal cord injuries. (28) It is broken up into four subscales including self-care, respiration and sphincter control, and mobility with a total score combining all 3 outcomes. It is scored from 0-100, where lower numbers indicate more dependence on others and higher numbers indicate less dependence. This tool can be applied practically to the study to investigate everyday function before and after patch application. SCIM was administered every 4 weeks of each period. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Pain Relief With Visual Analog (VAS) Pain Scale | Change in pain at 2,4,6,8, 10 and 12 weeks | score on a scale | MEAN | |
| PRIMARY | Change in Quality of Life as Measured by the World Health Organization Quality of Life (WHOQOL-BREF) | Every 4 weeks for 12 weeks | score on a scale | MEAN | |
| PRIMARY | Change in Spinal Cord Independence Measure (SCIM) | Every 4 weeks for12 weeks | score on a scale | MEAN |
Source ClinicalTrials.gov
Results by group24
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Experimental Group | 2 weeks | 3.586 | Standard Error 0.5345 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Control Group | 2 weeks | 5.494 | Standard Error 0.5775 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Experimental Group | 4 weeks | 4.041 | Standard Error 0.5345 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Control Group | 4 weeks | 5.677 | Standard Error 0.5345 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Experimental Group | 6 weeks | 4.984 | Standard Error 0.5540 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Control Group | 6 weeks | 5.768 | Standard Error 0.5345 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Experimental Group | 8 weeks | 4.184 | Standard Error 0.5540 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Control Group | 8 weeks | 4.834 | Standard Error 0.5544 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Experimental Group | 10 weeks | 4.284 | Standard Error 0.5540 | score on a scale |
| Change in Pain Relief With Visual Analog (VAS) Pain Scale | Control Group | 10 weeks | 4.753 | Standard Error 0.5769 | score on a scale |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 results by groupParticipant flow12
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Sequence 1 (12 Weeks) | STARTED | Qutenza Patch Followed by Low Dose Control Patch | 5 | |
| Sequence 1 (12 Weeks) | STARTED | Control Patch, Then Qutenza Patch | 6 | |
| Sequence 1 (12 Weeks) | COMPLETED | Qutenza Patch Followed by Low Dose Control Patch | 5 | |
| Sequence 1 (12 Weeks) | COMPLETED | Control Patch, Then Qutenza Patch | 6 | |
| Sequence 1 (12 Weeks) | NOT COMPLETED | Qutenza Patch Followed by Low Dose Control Patch | 0 | |
| Sequence 1 (12 Weeks) | NOT COMPLETED | Control Patch, Then Qutenza Patch | 0 | |
| Sequence 2 (12 Weeks) | STARTED | Qutenza Patch Followed by Low Dose Control Patch | 5 | |
| Sequence 2 (12 Weeks) | STARTED | Control Patch, Then Qutenza Patch | 6 | |
| Sequence 2 (12 Weeks) | COMPLETED | Qutenza Patch Followed by Low Dose Control Patch | 5 | |
| Sequence 2 (12 Weeks) | COMPLETED | Control Patch, Then Qutenza Patch | 6 |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 participant flowAdverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Experimental Group | 0 | 11 |
| Total, all-cause mortality | Control Group | 0 | 11 |
| Total, other adverse events | Experimental Group | 0 | 11 |
| Total, other adverse events | Control Group | 0 | 11 |
| Total, serious adverse events | Experimental Group | 0 | 11 |
| Total, serious adverse events | Control Group | 0 | 11 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Experimental Group vs Control Group: deaths from any cause | Trial comparisons |
| Experimental Group vs Control Group: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02441660
GET https://conductscience.org/api/trials/v1/NCT02441660/results?page=2